Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Receivables - Other (2021 - 2025)

Historic Receivables - Other for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $4.3 million.

  • ARS Pharmaceuticals' Receivables - Other rose 270855.26% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 270855.26%. This contributed to the annual value of $1.2 million for FY2024, which is 8895.71% up from last year.
  • Per ARS Pharmaceuticals' latest filing, its Receivables - Other stood at $4.3 million for Q3 2025, which was up 270855.26% from $2.0 million recorded in Q2 2025.
  • ARS Pharmaceuticals' Receivables - Other's 5-year high stood at $4.3 million during Q3 2025, with a 5-year trough of $122000.0 in Q2 2024.
  • Its 5-year average for Receivables - Other is $841000.0, with a median of $307000.0 in 2023.
  • As far as peak fluctuations go, ARS Pharmaceuticals' Receivables - Other tumbled by 6504.3% in 2024, and later surged by 270855.26% in 2025.
  • Quarter analysis of 5 years shows ARS Pharmaceuticals' Receivables - Other stood at $159000.0 in 2021, then soared by 33.96% to $213000.0 in 2022, then skyrocketed by 206.1% to $652000.0 in 2023, then soared by 88.96% to $1.2 million in 2024, then soared by 246.51% to $4.3 million in 2025.
  • Its Receivables - Other was $4.3 million in Q3 2025, compared to $2.0 million in Q2 2025 and $963000.0 in Q1 2025.